Results 21 to 30 of about 4,141 (163)
In Vitro Investigation of Auranofin as a Treatment for Clostridium difficile Infection
Drugs in R&D, 2020 Background Clostridium difficile infection is the leading cause of hospital-acquired gastrointestinal infection and incidence rates continue to rise. Clostridium difficile infection is becoming increasingly complex to treat owing to the rise in treatment
Christine Roder, Eugene Athan
doaj +1 more source
Will Auranofin Become a Golden New Treatment Against COVID-19?
Frontiers in Immunology, 2021 Auranofin is an FDA-approved disease-modifying anti-rheumatic drug that has been used for decades for treatment of rheumatoid arthritis. This gold(I) compound has anti-inflammatory properties because it reduces IL-6 expression via inhibition of the NF-κB-
Karine Sonzogni-Desautels +4 more
doaj +1 more source
PLoS ONE, 2022 Neisseria gonorrhoeae has been classified by the U.S. Centers for Disease Control and Prevention as an urgent threat due to the rapid development of antibiotic resistance to currently available antibiotics.
Ahmed E. M. Elhassanny +2 more
doaj +3 more sources
Auranofin, a thioredoxin reductase inhibitor, causes platelet death through calcium overload
Platelets, 2019 Platelets are central to normal hemostasis and must be tightly controlled to prevent thrombosis. However, drug treatments that also affect platelets could lead to unwanted side effects on hemostasis or thrombosis.
Matthew T. Harper
doaj +1 more source
Virulence, 2021 The slowing-down de novo drug-discovery emphasized the importance of repurposing old drugs. This is particularly true when combating infections caused by therapy-refractory microorganisms, such as Scedosporium species and Lomentospora prolificans. Recent
Hajar Yaakoub +6 more
doaj +1 more source
Computational and Structural Biotechnology Journal, 2023 Pseudomonas aeruginosa is a leading cause of hospital-acquired infections. Treatment of P. aeruginosa infections is difficult given its multiple virulence mechanisms, intrinsic antibiotic resistance mechanisms, and biofilm-forming ability.
Yingdan Zhang +6 more
doaj +1 more source
Auranofin is highly efficacious against Toxoplasma gondii in vitro and in an in vivo experimental model of acute toxoplasmosis. [PDF]
PLoS Neglected Tropical Diseases, 2014 The mainstay of toxoplasmosis treatment targets the folate biosynthetic pathways and has not changed for the last 50 years. The activity of these chemotherapeutic agents is restricted to one lifecycle stage of Toxoplasma gondii, they have significant ...
Rosa M Andrade +3 more
doaj +1 more source
Frontiers in Pharmacology, 2019 Pelvic and abdominal radiotherapy plays an important role in eradication of malignant cells; however, it also results in slight intestinal injury.
Eun Sang Lee +6 more
doaj +1 more source
Auranofin and Baicalin Inhibit Clostridioides difficile Growth and Sporulation: An In vitro Study
Journal of Pure and Applied Microbiology, 2022 Clostridioides difficile is a principal cause of hospital-acquired gastrointestinal infections, with sporulation and toxin production being key determinants in the disease pathogenesis.
Lamiaa A. Madkour
doaj +1 more source
Frontiers in Cellular and Infection Microbiology, 2021 Auranofin, a reprofiled FDA-approved drug originally designed to treat rheumatoid arthritis, has emerged as a promising anti-parasitic drug. It induces the accumulation of reactive oxygen species (ROS) in parasites, including Toxoplasma gondii.
Christopher I. Ma +10 more
doaj +1 more source